Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder.

Journal of clinical psychopharmacology - 1 Aug 2009

Leuchter Andrew F, McCracken James T, Hunter Aimee M, Cook Ian A, Alpert Jonathan E

Abstract excerpt

The placebo response shows pronounced interindividual variability. Placebos are postulated to act through central reward pathways that are modulated by monoamines. Because monoaminergic signaling is under strong genetic control, we hypothesized that common functional polymorphisms modulating monoaminergic tone would be related to degree of improvement during placebo treatment of subjects with major depressive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents
Share to Catechol O-Methyltransferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Depressive Disorder, Major

Share to Double-Blind Method

Share to Monoamine Oxidase

Share to Randomized Controlled Trials as Topic

Share to Severity of Illness Index

Share to Treatment Outcome

Source

Identifiers

PMID: 19593178
DOI: 10.1097/JCP.0b013e3181ac4aaf

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder.PMID 19593178Read ↗

Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome.Semantic proximity Read ↗

Catechol-O-methyltransferase (COMT) pharmacogenetics in the treatment response phenotypes of major depressive disorder (MDD).Semantic proximity Read ↗

Genetics and the placebo effect: the placebome.Semantic proximity Read ↗

The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study.Semantic proximity Read ↗

The opioid receptor mu 1 (OPRM1) rs1799971 and catechol-O-methyltransferase (COMT) rs4680 as genetic markers for placebo analgesia.Semantic proximity Read ↗

Effects of the Mu opioid receptor polymorphism (OPRM1 A118G) on pain regulation, placebo effects and associated personality trait measures.Semantic proximity Read ↗

Catechol-O-methyltransferase and monoamine oxidase A genotypes and drug response to conventional neuroleptics in schizophrenia.Semantic proximity Read ↗

Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder.Semantic proximity Read ↗

Catechol-o-methyltransferase polymorphism and susceptibility to major depressive disorder modulates psychological stress response.Semantic proximity Read ↗

Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine.Semantic proximity Read ↗

Catechol-O-methyltransferase genotype as modifier of superior responses to venlafaxine treatment in major depressive disorder.Semantic proximity Read ↗

The Catechol-O-methyltransferase Val(108/158)Met Genetic Polymorphism cannot be Recommended as a Biomarker for the Prediction of Venlafaxine Efficacy in Patients Treated in Psychiatric Settings.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.